CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Mogamulizumab, an anti-CCR4 antibody that has been de-fucosylated, lowers the levels of CCR4+ T cells and CCR4+ Tregs in individuals with cutaneous T-cell lymphoma [59].